NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

DBV Technologies S.A. (DBVT) Stock Analysis

DBV Technologies S.A. (DBVT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DBVT

$9.62

+$0.14 (+1.48%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DBVT with… →

DBVT Key Statistics

As of Oct 21, 2026
Trading
Open
$9.53
Previous Close
$9.48
Day's Range
9.53–9.92
52-Week Range
8.63–26.19
Volume
1.41M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.24
Valuation
Market Cap
$604.60M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
120.06
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.50
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$146.95M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
62.85M
1-Year Return
−39.76%
Dividend and dates
Earnings Date
October 28, 2026
Avg Volume
344.15K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DBVT closed at $9.62, −39.76% over 1 year.

DBV Technologies S.A. (DBVT) has a market capitalization of $604.60M.

In fiscal 2025, DBVT reported revenue of $0.00.

DBVT Stock Return by Calendar Year

DBV Technologies S.A. (DBVT) 10-year return: what $10,000 became

1 year
$10,000 $6,024
−39.76%
5 years
$10,000 $8,620
−13.80%
10 years
$10,000 $1,352
−86.48%

If you had invested $10,000 in DBV Technologies S.A. (DBVT) 10 years ago, at the close on October 21, 2016, it would have been worth $1,352 at the close on October 21, 2026: −86.48% in total, −18.13% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−49.82%
2025+520.39%
2024+62.12%
2023−37.71%
2022−4.38%
2021−38.93%
2020−75.51%
2019+66.67%
2018−73.90%
2017−29.97%
2016 (partial year)+4.15%

As of October 21, 2026.

DBVT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$146.95M—
2024$0.00−$113.92M—
2023$0.00−$72.73M—
2022$0.00−$96.27M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$147.05M−$146.95M—
2024$0.00—−$116.59M−$113.92M—
2023$0.00—−$76.43M−$72.73M—
2022$0.00—−$96.63M−$96.27M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DBVT Valuation vs Biotechnology Median

Median of 608 stocks
MetricDBVTBiotechnology medianvs median
P/S ratio120.0613.309.0x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

DBV Technologies S.A. (DBVT) is capitalised at $604.60M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 170.

Over the past 52 weeks the price has ranged from $8.63 to $26.19. The most recent close on file for DBVT is $9.62, dated October 21, 2026. That is +$0.14 (+1.48%) against the previous close. The latest close sits 11.47% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $146.95M. Trailing earnings per share are −3.5.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 120.06 times revenue. On price-to-sales that is 9 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −39.76%. Across 10 years the annualized return works out at −18.13%. The reported beta is −0.24. Annualized volatility over the trailing 10 years is 190.15%.

Growth & Income

No dividend is on file for DBVT.

2026 is still running; the total return is −49.82% year to date. Across the complete calendar years on file, 2025 returned +520.39% and 2020 returned −75.51%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

DBV Technologies S.A. (DBVT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
DBV Technologies S.A. DBVT $604.60M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. DBV Technologies S.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Visit website →